PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fi…
Author: Business Wire
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
DUBLIN–(BUSINESS WIRE)–The New England Journal of Medicine published Phase 3 trial data for Horizon Therapeutics’ TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease.
Tangible Science Announces Successful 2019 and Timing for Tangible Boost Launch
REDWOOD CITY, Calif.–(BUSINESS WIRE)– #GSLS–Tangible Science recaps 2019 highlights and sets timing for launch of Tangible Boost, a conditioner that repairs wear on coated contact lenses.
Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
FARMINGTON HILLS, Michigan–(BUSINESS WIRE)–Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it …
Il Medical Retina Center (istituto al vertice) in Italia adotta EyeArt AI Eye Screening System di Eyenuk
LOS ANGELES–(BUSINESS WIRE)–Eyenuk Inc. azienda globale specializzata in tecnologia medica manovrata da intelligenza artificiale (IA) e servizi e protagonista nelle applicazioni del mondo reale per AI Eye Screening™, oggi ha annunciato che il Medical…
EyeBuyDirect and Tan France Launch Exclusive Eyewear Collection that Celebrates YOU!
AUSTIN, Texas–(BUSINESS WIRE)–Tan France, resident fashion expert on the hit Netflix show Queer Eye, is known for his fashion-forward but relatable aesthetic, as well as his sense of inclusivity. “As a stylist, my goal is to help people be the best v…
FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics today announced that the FDA has approved TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
Covenant Surgical Partners Rebrands Company, Announces Partnership With Texas Eye Care Network
NASHVILLE, Tenn. & CORPUS CHRISTI, Texas–(BUSINESS WIRE)–Signaling its evolution from an ambulatory surgery center company to a physician services organization, Covenant Surgical Partners has rebranded to Covenant Physician Partners, officials announ…
SeniorWell Expands Service to Minnesota
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare and logistics company, today announced its expansion into Minnesota.
Contemporary Pediatrics® Unveils Results of Annual Issues and Attitudes Survey
CRANBURY, N.J.–(BUSINESS WIRE)– #burnout–The survey of over 14,000 pediatricians reveals the top opportunities and struggles facing physicians in the specialty today
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
テジ・コーリ財団が失明治癒のための角膜組織再生に向け一歩前進
ロンドン–(BUSINESS WIRE)–（ビジネスワイヤ） — テジ・コーリ財団は、当財団が最近取得した専有技術を生合成注入材料の「接着充填剤」へと発展させるべく、カナダのモントリオールおよび英国のムーアフィールズ眼科病院の研究者らとの共同研究に取り掛かる準備を整え、角膜失明の非外科的治療に向けて一歩近づきました。 この生合成ソリューションは、体温でゲル状態を取り、組織接着剤として機能するように変わることができる液体です。この生合成材料は、角膜穿孔をふさいで角膜組織の再生をもたし得るもので、…
Tej Kohli基金会向角膜组织再生法治愈失明又迈近了一步
伦敦–(BUSINESS WIRE)–(美国商业资讯)–Tej Kohli基金会(The Tej Kohli Foundation)准备与加拿大蒙特利尔和英国Moorfields眼科医院的研究人员展开合作，将基金会最近收购的专利技术开发为生物合成“胶填充剂”针剂，向角膜失明的非手术治疗又迈近了一步。 该生物合成溶液是液态，在人体温度下会变成凝胶，然后可以改性，用作组织胶。该生物合成材料有望封闭角膜穿孔并引起角膜组织再生，这样便无需进行角膜移植手术，降低排斥风险。 就像蛀牙空洞一样，“填充剂”将…
Tej Kohli基金會朝向角膜組織再生法治癒失明又邁進了一步
倫敦–(BUSINESS WIRE)–(美國商業資訊)–Tej Kohli基金會(The Tej Kohli Foundation)準備與加拿大蒙特婁和英國Moorfields眼科醫院的研究人員合作，將基金會最近收購的專利技術開發為生物合成「黏膠填充劑」針劑，朝向角膜失明的非手術治療又邁進了一步。 該生物合成溶液是液態，在人體溫度下會變成凝膠，然後可以調整用作組織膠。該生物合成材料有望封閉角膜穿孔並使得角膜組織再生，這樣便無需進行角膜移植手術，降低排斥風險。 就像蛀牙空洞一樣，「填充劑」將在切…
Leading Medical Retina Center in Italy Adopts Eyenuk’s EyeArt AI Eye Screening System
LOS ANGELES–(BUSINESS WIRE)– #ai4healthcare–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that the Medical Retina Center an…
North America Eyewear Market Expected to Grow with a CAGR of 2.4% During the Forecast Period, 2019-2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Eyewear Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering. Looking forward, the publisher expects the market to reach…
Resumen: Immervision anuncia nuevos acuerdos de licencia con los fabricantes de lentes ACE Solutech Co. (Corea) y Zhonglan Electronic Technology Co., Ltd (ZET en China)
MONTREAL–(BUSINESS WIRE)–Immervision, desarrollador y licenciador de tecnología de imágenes y óptica de ángulo amplio patentada, con sede en Montreal, ha anunciado dos nuevos acuerdos de licencia para la producción y distribución de lentes panomorfas…
Global Contact Lenses Market 2020-2024 | 6% CAGR Projection Through 2024 | Technavio
LONDON–(BUSINESS WIRE)– #ConsumerDiscretionary–The global contact lenses market is expected to post a CAGR of more than 6% during the period 2020-2024, according to Technavio.
Die Tej Kohli Foundation rückt der Regeneration des Hornhautgewebes zur Heilung von Blindheit einen Schritt näher
LONDON–(BUSINESS WIRE)–Während die Tej Kohli Foundation der Möglichkeit einer Behandlung der hornhautbedingten Erblindung ohne Operation einen Schritt näher gekommen ist, bereitet sie sich auf eine Zusammenarbeit mit Forschern in Montreal (Kanada) un…